FXR agonists targeting the gut-liver axis are promising for NAFLD/NASH for they not only relieve hepatic steatosis but also resolve fibrosis at histology level by antagonizing NFκB [285, 286]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.